April 25, 2019Open Access

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

Key Points

Key points are not available for this paper at this time.

Abstract

Different PD-1 and PD-L1 inhibitors appear to have varying treatment-related adverse events; a comprehensive summary of the incidences of treatment-related adverse events in clinical trials provides an important guide for clinicians.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Wang et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69d74dbdb54ccf0cfef30ce3 — DOI: https://doi.org/10.1001/jamaoncol.2019.0393

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Untitled· 2017 · 6 citations
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens· 2017 · 1,065 citations
Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab· 2016 · 248 citations
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer· 2018 · 386 citations

Authors

Yucai Wang

Shouhao Zhou

Fang Yang

Journals

JAMA Oncology

Actions

Institutions

The University of Texas MD Anderson Cancer Center

Mayo Clinic

University of Tennessee at Knoxville

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion